RESUMEN
BACKGROUND: Only about 50% of intensive care unit (ICU) patients reach a free trough concentration above MIC (100% fT > MIC) of beta-lactam antibiotics. Although dose adjustments based on therapeutic drug monitoring (TDM) could be beneficial, TDM is not widely available. We investigated serum creatinine-based estimated GFR (eGFR) as a rapid screening tool to identify ICU patients at risk of insufficient exposure. METHOD: Ninety-three adult patients admitted to four ICUs in southeast Sweden treated with piperacillin/tazobactam, meropenem, or cefotaxime were included. Beta-lactam trough concentrations were measured. The concentration target was set to 100% fT > MICECOFF (2, 4, and 16 mg/L based on calculated free levels for meropenem, cefotaxime, and piperacillin, respectively). eGFR was primarily determined via Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) and compared to three other eGFR equations. Data was analysed using logistic regression and receiver operative characteristic (ROC) curves. RESULTS: With intermittent standard dosing, insufficient exposure was common in patients with a relative eGFR ≥48mL/min/1.73m2 [85%, (45/53)], particularly when treated with cefotaxime [96%, (24/25)]. This eGFR cut-off had a sensitivity of 92% and specificity of 82% (AUC 0.871, p < 0.001) in identifying insufficient exposure. In contrast, patients with eGFR <48mL/min/1.73m2 had high target attainment [90%, (36/40)] with a wide variability in drug exposure. There was no difference between the four eGFR equations (AUC 0.866-0.872, cut-offs 44-51 ml/min/1.73m2). CONCLUSION: Serum creatinine-based eGFR is a simple and widely available surrogate marker with potential for early identification of ICU patients at risk of insufficient exposure to piperacillin, meropenem, and cefotaxime.
Asunto(s)
Tasa de Filtración Glomerular , Unidades de Cuidados Intensivos , Antibióticos Betalactámicos , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antibióticos Betalactámicos/administración & dosificación , Cefotaxima/sangre , Cefotaxima/uso terapéutico , Creatinina/sangre , Monitoreo de Drogas/métodos , Tasa de Filtración Glomerular/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Curva ROC , SueciaRESUMEN
BACKGROUND: Biochemical markers of bone turnover (BTMs), such as the bone alkaline phosphatase (bALP), procollagen type I N propeptide (PINP), serum cross-linked C-telopeptides of type I collagen (bCTx), and urinary cross-linked N-telopeptides of type I collagen (NTx), are used to manage therapy monitoring in osteoporotic patients. This systematic review analyzed the potential of these BMTs in predicting the clinical outcomes in terms of BMD, t-score, rate of fractures, and adverse events during the therapy setting in postmenopausal osteoporosis. METHODS: All randomized clinical trials (RCTs) reporting data on biomarkers for postmenopausal osteoporosis were accessed. Only articles reporting quantitative data on the level of biomarkers at baseline and on the outcomes of interest at the last follow-up were eligible. RESULTS: A total of 36,706 patients were retrieved. Greater values of bALP were associated with a greater rate of vertebral (P = 0.001) and non-vertebral fractures (P = 0.0001). Greater values of NTx at baseline were associated with a greater rate of adverse events at the last follow-up (P = 0.02). Greater values of CTx at baseline were associated with a greater rate of adverse events leading to discontinuation (P = 0.04), gastrointestinal adverse events (P = 0.0001), musculoskeletal adverse events (P = 0.04), and mortality (P = 0.04). Greater values of PINP at baseline were associated with greater rates of gastrointestinal adverse events (P = 0.02) at the last follow-up. CONCLUSION: The present analysis supports the adoption of BMTs during pharmacological therapy setting of patients suffering from osteoporosis. LEVEL OF EVIDENCE: I, systematic review of RCTs.
Asunto(s)
Fosfatasa Alcalina/sangre , Biomarcadores/sangre , Conservadores de la Densidad Ósea/uso terapéutico , Osteoporosis Posmenopáusica/diagnóstico , Osteoporosis Posmenopáusica/tratamiento farmacológico , Fragmentos de Péptidos/sangre , Procolágeno/sangre , Anciano , Anciano de 80 o más Años , Biomarcadores/orina , Densidad Ósea , Conservadores de la Densidad Ósea/efectos adversos , Cefotaxima/análogos & derivados , Cefotaxima/sangre , Colágeno Tipo I/orina , Femenino , Humanos , Persona de Mediana Edad , Monitoreo Fisiológico , Osteoporosis Posmenopáusica/metabolismo , Péptidos/orina , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Critical illness has been shown to affect the pharmacokinetics of antibiotics, which can lead to ineffective antibiotic exposure and the potential emergence of resistant bacteria. The lack of studies describing antibiotic pharmacokinetics in critically ill children has led to significant off-label dosing. This is, in part, due to the ethical and physiological challenges of removing frequent, large-volume samples from children. Capillary microsampling facilitates the collection of small volumes of blood samples to conduct clinical pharmacokinetic studies. A sensitive, rapid, and accurate ultra-high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) bioanalytical method to measure cefotaxime and desacetylcefotaxime in 2.8 µL of plasma was developed and validated. Plasma samples were treated with acetonitrile and analytes were separated using a Kinetex C8 (100 × 2.1 mm) column. The chromatographic separation was established using a gradient method, with the mobile phases consisting of acetonitrile and ammonium acetate. An electrospray ionization source interface operated in a positive mode for the multiple reaction monitoring MS/MS analysis of cefotaxime, desacetylcefotaxime, and deuterated cefotaxime (internal standard). The bioanalytical method using microsample volumes met requirements for method validation for both analytes. Cefotaxime had precision within ± 7.3% and accuracy within ± 5% (concentration range of 0.5 to 500 mg/L). Desacetylcefotaxime had precision within ± 9.5% and accuracy within ± 3.5% (concentration range of 0.2 to 10 mg/L). The bioanalytical method was applied for the quantification of cefotaxime and its metabolite to 20 capillary microsamples collected at five time points in one dosing interval from five critically ill children.
Asunto(s)
Antibacterianos/sangre , Cefotaxima/análogos & derivados , Cefotaxima/sangre , Niño , Cromatografía Líquida de Alta Presión/métodos , Enfermedad Crítica/terapia , Monitoreo de Drogas/métodos , Humanos , Límite de Detección , Proyectos Piloto , Reproducibilidad de los Resultados , Espectrometría de Masas en Tándem/métodosRESUMEN
A rapid and highly sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay was developed for quantification of 7 antibiotics in low sample volumes (50⯵L): amoxicillin, azithromycin, cefotaxime, ciprofloxacin, meropenem, metronidazole and piperacillin, for both routine monitoring and pharmacokinetic studies. After protein precipitation by acetonitrile, the antibiotics were separated on an Acquity UPLC HSS T3 column (run time, 4â¯min). The mobile phase consisted of a mixture of (A) ammonium acetate (pH 2.4; 5â¯mM) and (B) acetonitrile acidified with 0.1% formic acid, delivered at 500⯵l/min in a gradient elution mode. Total time run was 2.75â¯min. Ions were detected in the turbo-ion-spray-positive and multiple-reaction-monitoring modes. The assay was accurate and reproductible for the quantification of the seven antibiotics in serum samples over large concentration ranges.
Asunto(s)
Antibacterianos/sangre , Análisis Químico de la Sangre/métodos , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas en Tándem/métodos , Adolescente , Amoxicilina/sangre , Azitromicina/sangre , Calibración , Cefotaxima/sangre , Niño , Preescolar , Ciprofloxacina/sangre , Infecciones por Escherichia coli/tratamiento farmacológico , Humanos , Lactante , Recién Nacido , Leucemia Mieloide Aguda/complicaciones , Leucemia Mieloide Aguda/microbiología , Límite de Detección , Masculino , Meropenem/sangre , Metronidazol/sangre , Pediatría , Piperacilina/sangre , Reproducibilidad de los ResultadosRESUMEN
Reduced target attainment of ß-lactam antibiotics is reported in critically ill patients. However, as target attainment of cefotaxime in severely ill pediatric sepsis patients may differ from adults due to age-related variation in pharmacokinetics, we aimed to assess target attainment of cefotaxime in this pilot study using meningococcal septic shock patients as a model for severe sepsis. Secondary analysis of prospectively collected data from a randomized controlled trial. Children with meningococcal septic shock (1 month to 18 years) included in this study received cefotaxime 100-150 mg/kg/day as antibiotic treatment. Left-over plasma samples were analyzed using LC-MS/MS to determine cefotaxime concentrations. MIC values from EUCAST were used to determine target attainment of cefotaxime for Neisseria meningitidis (0.125 mg/l), but also for Streptococcus pneumoniae (0.5 mg/l), Enterobacteriaceae (1 mg/l), and Staphylococcus aureus (4 mg/l). Target attainment was adequate when all samples exceeded MIC or fourfold MIC values. One thirty-six plasma samples of 37 severe septic shock patients were analyzed for cefotaxime concentrations. Median age was 2 years with a median PRISM-score of 24 and mortality of 24.8%. The median unbound cefotaxime concentration was 4.8 mg/l (range 0-48.7). Target attainment ranged from 94.6% for the MIC of N. meningitidis to 16.2% for fourfold the MIC S. aureus. Creatinine levels were significantly correlated with cefotaxime levels. Target attainment of cefotaxime with current dosing guidelines seems to be adequate for N. meningitidis but seems to fail for more frequently encountered pathogens in severely ill children.
Asunto(s)
Antibacterianos/farmacocinética , Cefotaxima/farmacocinética , Infecciones Meningocócicas/tratamiento farmacológico , Sepsis/tratamiento farmacológico , Choque Séptico/tratamiento farmacológico , Adolescente , Antibacterianos/sangre , Antibacterianos/uso terapéutico , Cefotaxima/sangre , Cefotaxima/uso terapéutico , Niño , Preescolar , Enfermedad Crítica , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Infecciones Meningocócicas/sangre , Infecciones Meningocócicas/complicaciones , Neisseria meningitidis/efectos de los fármacos , Proyectos Piloto , Sepsis/microbiología , Choque Séptico/microbiologíaRESUMEN
INTRODUCTION: Optimisation of antibiotic therapy for extracorporeal membrane oxygenation (ECMO) patients remains a pharmacological challenge. The objective of this study was to observe the plasma concentrations of commonly used antibiotics in intensive care for patients treated with extracorporeal membrane oxygenation. PATIENTS AND METHODS: The PHARMECMO study was a pilot, prospective study, conducted in a cardiac surgery intensive care unit. Every adult patient under ECMO support, with known or suspected sepsis and receiving antibiotic therapy, was eligible for inclusion. Plasma concentrations of antibiotics were determined by a combination of liquid chromatography and mass spectrometry. RESULTS: Forty-four eligible patients were enrolled for 68 inclusions on a twelve-month period. For the association piperacillin-tazobactam (n=19), 68.7% of CT50 and 93.7% of Cmin reached the pharmacokinetic goals defined (64 mg.L-1 for CT50 and 16 mg.L-1 for Cmin). For cefotaxime (n=12), the pharmacokinetic goals (4 mg.L-1 for CT50 and 1 mg.L-1 for Cmin) were achieved in 100% of the cases for CT50 and in 81.8% of the cases for Cmin. Regarding imipenem (n=10), the pharmacokinetic goals were 16 mg.L-1 for CT50 and 4 mg.L-1 for Cmin. Only one CT50 was above 16 mg.L-1. For Cmin, 60% of the doses did not reach the target concentration. In our 10 patients, only one patient was considered as reaching the pharmacokinetic goals. Finally, for amikacin (n=6), four Cmax (66.7%) were infra-therapeutics for a target between 60 and 80 mg.L-1. CONCLUSION: These preliminary results suggest that therapeutic drug monitoring could optimise the achievement of pharmacokinetic objectives associated with an effective antibiotic therapy. For most patients, the recommended doses of imipenem and amikacin did not achieve the pK targets.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/sangre , Monitoreo de Drogas/métodos , Oxigenación por Membrana Extracorpórea , Sepsis/tratamiento farmacológico , Anciano , Amicacina/administración & dosificación , Amicacina/sangre , Cefotaxima/administración & dosificación , Cefotaxima/sangre , Combinación Cilastatina e Imipenem/administración & dosificación , Combinación Cilastatina e Imipenem/sangre , Unidades de Cuidados Coronarios , Oxigenación por Membrana Extracorpórea/métodos , Femenino , Gentamicinas/administración & dosificación , Gentamicinas/sangre , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Combinación Piperacilina y Tazobactam/administración & dosificación , Combinación Piperacilina y Tazobactam/sangre , Estudios Prospectivos , Sepsis/sangre , Sepsis/mortalidad , Tobramicina/administración & dosificación , Tobramicina/sangreRESUMEN
Cefotaxime is the first-line treatment for meningitis in neonates and young infants. However, limited data on cefotaxime cerebrospinal fluid (CSF) concentrations in neonates and young infants were available. The aim of the present study was to evaluate the penetration of cefotaxime into CSF in neonates and young infants. Blood and CSF samples were collected from neonates and young infants treated with cefotaxime using an opportunistic pharmacokinetic sampling strategy, and concentrations were quantified by high-performance liquid chromatography-tandem mass spectrometry. The analysis was performed using NONMEM and R software. Thirty neonates and young infants (postmenstrual age range, 25.4 to 47.4 weeks) were included. A total of 67 plasma samples and 30 CSF samples were available for analysis. Cefotaxime plasma and CSF concentrations ranged from 2.30 to 175.42 mg/liter and from 0.39 to 25.38 mg/liter, respectively. The median ratio of the CSF concentration to the plasma concentration was 0.28 (range, 0.06 to 0.76). Monte Carlo simulation demonstrated that 88.4% and 63.9% of hypothetical neonates treated with 50 mg/kg of body weight three times a day (TID) would reach the pharmacodynamic target (the percentage of the dosing interval that the free antimicrobial drug concentration remains above the MIC, 70%) using the standard EUCAST MIC susceptibility breakpoints of 2 mg/liter and 4 mg/liter, respectively. The penetration of cefotaxime into the CSF of neonates and young infants was evaluated using an opportunistic sampling approach. A dosage regimen of 50 mg/kg TID could cover the most causative pathogens with MICs of <2 mg/liter. Individual dosage adaptation was required for more resistant bacterial strains, such as Staphylococcus aureus.
Asunto(s)
Cefotaxima/líquido cefalorraquídeo , Cefotaxima/sangre , Cefotaxima/farmacocinética , Cromatografía Líquida de Alta Presión , Humanos , Lactante , Recién Nacido , Modelos TeóricosRESUMEN
The pharmacokinetic profile of most drugs is dependent on the patient's covariates and may be influenced by the disease. Cefotaxime is frequently prescribed in pediatric patients with sickle cell disease (SCD), characterized by vaso-occlusive complications, chronic hemolytic anemia, and a defective immunological function predisposing the individual to severe infection. Data on the impact of the disease on the disposition of cefotaxime are missing. In the present study, our aims were to determine cefotaxime pharmacokinetics when prescribed to children with SCD for suspected or proven bacterial infection, identify significant covariates, and perform Monte Carlo simulations to optimize the drug dosage. Cefotaxime serum concentrations were measured in 78 pediatric SCD patients receiving cefotaxime intravenously at a daily dose of 200 mg/kg of body weight in three or four divided doses over 30 min. A total of 107 concentrations were available for pharmacokinetic analysis. A population pharmacokinetic model was developed with NONMEM software and used for Monte Carlo simulations. Cefotaxime concentrations ranged from 0.05 to 103.7 mg/liter. Cefotaxime pharmacokinetics were best described by a one-compartment model: the median estimated weight-normalized volume of distribution and clearance were 0.42 liter/kg (range, 0.2 to 1.1 liter/kg) and 0.38 liter/h/kg (range, 0.1 to 1.2 liter/h/kg). Cefotaxime clearance increased by 22% in patients with acute chest syndrome. Dosing optimization, performed using EUCAST MIC susceptibility breakpoints, showed that a dose of 100 mg/kg/6 h should be used, depending on the patient's characteristics and clinical presentation, in order to reach a value of the percentage of time that the drug concentration exceeded the MIC under steady-state pharmacokinetic conditions of 80% in 80% of the patients when targeting sensitive Gram-positive cocci and Gram-negative bacilli with MICs of 1 mg/liter or below.
Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Antibacterianos/sangre , Antibacterianos/farmacocinética , Cefotaxima/sangre , Cefotaxima/farmacocinética , Adolescente , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Cefotaxima/administración & dosificación , Cefotaxima/uso terapéutico , Niño , Preescolar , Femenino , Bacterias Gramnegativas/efectos de los fármacos , Humanos , Lactante , Masculino , Pruebas de Sensibilidad Microbiana , Método de MontecarloRESUMEN
In older adults, few studies confirm that adequate concentrations of antibiotics are achieved using current dosage regimens of intravenous ß-lactam antibiotics. Our objective was to investigate trough concentrations of cefotaxime, meropenem, and piperacillin in older adults hospitalized with infection. We included 102 patients above 70 years of age. Total trough antibiotic concentrations were measured and related to suggested target intervals. Information on antibiotic dose, patient characteristics, and 28-day outcomes were collected from medical records and regression models were fitted. Trough concentrations for all three antibiotics exhibited considerable variation. Mean total trough concentrations for cefotaxime, meropenem, and piperacillin were 6.5 mg/L (range 0-44), 3.4 mg/L (range 0-11), and 30.2 mg/L (range 1.2-131), respectively. When a target range of non-species-related breakpoint - 5× non-species-related breakpoint was applied, only 36% of patients had both values within the target range. Regression models revealed that severe sepsis was associated with varying concentration levels and increasing age and diminishing kidney function with high concentration levels. The study was not powered to demonstrate consequences in clinical outcomes. Conclusively, in older adults treated with cefotaxime, meropenem, or piperacillin-tazobactam, trough antibiotic concentrations varied considerably. Better predictors to guide dosing regimens of ß-lactam antibiotics or increased use of therapeutic drug monitoring are potential ways to address such variations.
Asunto(s)
Infecciones Bacterianas , Sepsis , beta-Lactamas/sangre , beta-Lactamas/farmacocinética , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/epidemiología , Infecciones Bacterianas/mortalidad , Cefotaxima/sangre , Cefotaxima/farmacocinética , Monitoreo de Drogas , Femenino , Humanos , Tiempo de Internación/estadística & datos numéricos , Masculino , Meropenem , Readmisión del Paciente/estadística & datos numéricos , Ácido Penicilánico/análogos & derivados , Ácido Penicilánico/sangre , Ácido Penicilánico/farmacocinética , Piperacilina/sangre , Piperacilina/farmacocinética , Combinación Piperacilina y Tazobactam , Estudios Prospectivos , Sepsis/tratamiento farmacológico , Sepsis/epidemiología , Sepsis/mortalidad , Suecia/epidemiología , Tienamicinas/sangre , Tienamicinas/farmacocinéticaAsunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana , Neumonía Neumocócica/tratamiento farmacológico , Streptococcus pneumoniae/efectos de los fármacos , beta-Lactamas/farmacología , Amoxicilina/sangre , Amoxicilina/farmacocinética , Amoxicilina/farmacología , Antibacterianos/sangre , Antibacterianos/farmacocinética , Cefotaxima/sangre , Cefotaxima/farmacocinética , Cefotaxima/farmacología , Industria Farmacéutica/economía , Industria Farmacéutica/ética , Humanos , Pruebas de Sensibilidad Microbiana/ética , Pruebas de Sensibilidad Microbiana/métodos , Penicilinas/sangre , Penicilinas/farmacocinética , Penicilinas/farmacología , Neumonía Neumocócica/sangre , Neumonía Neumocócica/microbiología , Política , Guías de Práctica Clínica como Asunto , Streptococcus pneumoniae/crecimiento & desarrollo , Terminología como Asunto , beta-Lactamas/sangre , beta-Lactamas/farmacocinéticaRESUMEN
Cefotaxime is one of the most frequently prescribed antibiotics for the treatment of Gram-negative bacterial sepsis in neonates. However, the dosing regimens routinely used in clinical practice vary considerably. The objective of the present study was to conduct a population pharmacokinetic study of cefotaxime in neonates and young infants in order to evaluate and optimize the dosing regimen. An opportunistic sampling strategy combined with population pharmacokinetic analysis using NONMEM software was performed. Cefotaxime concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry. Developmental pharmacokinetics-pharmacodynamics, the microbiological pathogens, and safety aspects were taken into account to optimize the dose. The pharmacokinetic data from 100 neonates (gestational age [GA] range, 23 to 42 weeks) were modeled with an allometric two-compartment model with first-order elimination. The median values for clearance and the volume of distribution at steady state were 0.12 liter/h/kg of body weight and 0.64 liter/kg, respectively. The covariate analysis showed that current weight, GA, and postnatal age (PNA) had significant impacts on cefotaxime pharmacokinetics. Monte Carlo simulations demonstrated that the current dose recommendations underdosed older newborns. A model-based dosing regimen of 50 mg/kg twice a day to four times a day, according to GA and PNA, was established. The associated risk of overdose for the proposed dosing regimen was 0.01%. We determined the population pharmacokinetics of cefotaxime and established a model-based dosing regimen to optimize treatment for neonates and young infants.
Asunto(s)
Antibacterianos/farmacocinética , Cefotaxima/farmacocinética , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Modelos Estadísticos , Sepsis/tratamiento farmacológico , Antibacterianos/sangre , Antibacterianos/farmacología , Peso Corporal , Cefotaxima/sangre , Cefotaxima/farmacología , Cromatografía Líquida de Alta Presión , Simulación por Computador , Esquema de Medicación , Cálculo de Dosificación de Drogas , Femenino , Edad Gestacional , Infecciones por Bacterias Gramnegativas/microbiología , Infecciones por Bacterias Gramnegativas/patología , Humanos , Lactante , Recién Nacido , Unidades de Cuidados Intensivos , Masculino , Método de Montecarlo , Sepsis/microbiología , Sepsis/patología , Espectrometría de Masas en TándemRESUMEN
A simple and rapid ultra-high-performance liquid chromatography (UHPLC) method using UV detection was developed for the simultaneous determination of eight ß-lactam antibiotics in human plasma, including four penicillins, amoxicillin (AMX), cloxacillin (CLX), oxacillin (OXA), and piperacillin (PIP), and four cephalosporins, cefazolin (CFZ), cefepime (FEP), cefotaxime (CTX), and ceftazidime (CAZ). One hundred-microliter samples were spiked with thiopental as an internal standard, and proteins were precipitated by acetonitrile containing 0.1% formic acid. Separation was achieved on a pentafluorophenyl (PFP) column with a mobile phase composed of phosphoric acid (10 mM) and acetonitrile in gradient elution mode at a flow rate of 500 µl/min. Detection was performed at 230 nm for AMX, CLX, OXA, and PIP and 260 nm for CFZ, FEP, CTX, and CAZ. The total analysis time did not exceed 13 min. The method was found to be linear at concentrations ranging from 2 to 100 mg/liter for each compound, and all validation parameters fulfilled international requirements. Between- and within-run accuracy errors ranged from -5.2% to 11.4%, and precision was lower than 14.2%. This simple method requires small-volume samples and can easily be implemented in most clinical laboratories to promote the therapeutic drug monitoring of ß-lactam antibiotics. The simultaneous determination of several antibiotics considerably reduces the time to results for clinicians, which may improve treatment efficiency, especially in critically ill patients.
Asunto(s)
Antibacterianos/sangre , beta-Lactamas/sangre , Amoxicilina/sangre , Cefazolina/sangre , Cefepima , Cefotaxima/sangre , Ceftazidima/sangre , Cefalosporinas/sangre , Cromatografía Líquida de Alta Presión/métodos , Cloxacilina/sangre , Monitoreo de Drogas/métodos , Humanos , Oxacilina/sangre , Piperacilina/sangre , Rayos UltravioletaRESUMEN
The objective of this study was to describe the pharmacokinetics of cefotaxime (CTX) in critically ill patients with acute kidney injury (AKI) when treated with continuous renal replacement therapy (CRRT) in the intensive care unit (ICU). This single-center prospective observational pilot study was performed among ICU-patients with AKI receiving ≥48 h concomitant CRRT and CTX. CTX was administered intravenously 1,000 mg (bolus) every 6 h for 4 days. CRRT was performed as continuous venovenous hemofiltration (CVVH). Plasma concentrations of CTX and its active metabolite desacetylcefotaxime (DAC) were measured during CVVH treatment. CTX plasma levels and patient data were used to construct concentration-time curves. By using this data, the duration of plasma levels above 4 mg/liter (four times the MIC) was calculated and analyzed. Twenty-seven patients were included. The median CTX peak level was 55 mg/liter (range, 19 to 98 mg/liter), the median CTX trough level was 12 mg/liter (range, 0.8 to 37 mg/liter), and the median DAC plasma level was 15 mg/liter (range, 1.5 to 48 mg/liter). Five patients (19%) had CTX plasma levels below 4 mg/liter at certain time points during treatment. In at least 83% of the time any patient was treated with CTX, the CTX plasma level stayed above 4 mg/liter. A dosing regimen of 1,000 mg of CTX given four times daily is likely to achieve adequate plasma levels in patients with AKI treated with CVVH. Dose reduction might be a risk for suboptimal treatment.
Asunto(s)
Lesión Renal Aguda/terapia , Antibacterianos/farmacocinética , Cefotaxima/análogos & derivados , Cefotaxima/sangre , Cefotaxima/farmacocinética , Anciano , Antibacterianos/uso terapéutico , Cefotaxima/uso terapéutico , Enfermedad Crítica , Femenino , Humanos , Unidades de Cuidados Intensivos , Masculino , Proyectos Piloto , Estudios Prospectivos , Terapia de Reemplazo RenalRESUMEN
We investigated the efficacies of cefotaxime (CTX) and amoxicillin (AMX)-clavulanate (CLA) (AMC) against extended-spectrum-ß-lactamase (ESBL)-producing Escherichia coli in vitro and in a murine model of urinary tract infection (UTI). MICs, the checkerboard dilution method, and time-kill curves were used to explore the in vitro synergism between cefotaxime and amoxicillin-clavulanate against two isogenic E. coli strains-CFT073-RR and its transconjugant, CFT073-RR Tc bla(CTX-M-15)-harboring a bla(CTX-M-15) plasmid and a bla(OXA-1) plasmid. For in vivo experiments, mice were separately infected with each strain and treated with cefotaxime, amoxicillin, and clavulanate, alone or in combination, or imipenem, using therapeutic regimens reproducing time of free-drug concentrations above the MIC (fT≥MIC) values close to that obtained in humans. MICs of amoxicillin, cefotaxime, and imipenem were 4/>1,024, 0.125/1,024, and 0.5/0.5 mg/liter, for CFT073-RR and CFT073-RR Tc bla(CTX-M-15), respectively. The addition of 2 mg/liter of clavulanate (CLA) restored the susceptibility of CFT073-RR Tc bla(CTX-M-15) to CTX (MICs of the CTX-CLA combination, 0.125 mg/liter). The checkerboard dilution method and time-kill curves confirmed an in vitro synergy between amoxicillin-clavulanate and cefotaxime against CFT073-RR Tc bla(CTX-M-15). In vivo, this antibiotic combination was similarly active against both strains and as effective as imipenem. In conclusion, the cefotaxime and amoxicillin-clavulanate combination appear to be an effective, easy, and already available alternative to carbapenems for the treatment of UTI due to CTX-M-producing E. coli strains.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Antibacterianos/farmacología , Cefotaxima/farmacología , Pielonefritis/tratamiento farmacológico , Infecciones Urinarias/tratamiento farmacológico , Escherichia coli Uropatógena/efectos de los fármacos , beta-Lactamasas/genética , Combinación Amoxicilina-Clavulanato de Potasio/sangre , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Animales , Antibacterianos/sangre , Antibacterianos/farmacocinética , Cefotaxima/sangre , Cefotaxima/farmacocinética , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Quimioterapia Combinada , Femenino , Expresión Génica , Humanos , Imipenem/farmacología , Ratones , Ratones Endogámicos CBA , Pruebas de Sensibilidad Microbiana , Plásmidos/química , Plásmidos/metabolismo , Pielonefritis/sangre , Pielonefritis/microbiología , Pielonefritis/patología , Infecciones Urinarias/sangre , Infecciones Urinarias/microbiología , Infecciones Urinarias/patología , Escherichia coli Uropatógena/enzimología , Escherichia coli Uropatógena/genética , Resistencia betalactámica/genética , beta-Lactamasas/metabolismoRESUMEN
Organic anion transporter 3 (OAT3, SLC22A8), a transporter expressed on the basolateral membrane of the proximal tubule, plays a critical role in the renal excretion of organic anions including many therapeutic drugs. The goal of this study was to evaluate the in vivo effects of the OAT3-Ile305Phe variant (rs11568482), present at 3.5% allele frequency in Asians, on drug disposition with a focus on cefotaxime, a cephalosporin antibiotic. In HEK293-Flp-In cells, the OAT3-Ile305Phe variant had a lower maximum cefotaxime transport activity, Vmax , [159 ± 3 nmol*(mg protein)(-1) /min (mean ± SD)] compared with the reference OAT3 [305 ± 28 nmol*(mg protein)(-1) /min, (mean ± SD), p < 0.01], whereas the Michaelis-Menten constant values (Km ) did not differ. In healthy volunteers, we found volunteers that were heterozygous for the Ile305Phe variant and had a significantly lower cefotaxime renal clearance (CLR ; mean ± SD: 84.8 ± 32.1 mL/min, n = 5) compared with volunteers that were homozygous for the reference allele (158 ± 44.1 mL/min, n = 10; p = 0.006). Furthermore, the net secretory component of cefotaxime renal clearance (CLsec ) was reduced in volunteers heterozygous for the variant allele [33.3 ± 31.8 mL/min (mean ± SD)] compared with volunteers homozygous for the OAT3 reference allele [97.0 ± 42.2 mL/min (mean ± SD), p = 0.01]. In summary, our study suggests that a low-frequency reduced-function polymorphism of OAT3 associates with reduced cefotaxime CLR and CL(sec) .
Asunto(s)
Antibacterianos/sangre , Antibacterianos/metabolismo , Cefotaxima/sangre , Cefotaxima/metabolismo , Riñón/metabolismo , Transportadores de Anión Orgánico Sodio-Independiente/genética , Adolescente , Adulto , Pueblo Asiatico/genética , Femenino , Frecuencia de los Genes , Células HEK293 , Humanos , Masculino , Transportadores de Anión Orgánico Sodio-Independiente/metabolismo , Polimorfismo Genético , Adulto JovenRESUMEN
Central nervous system (CNS) antibiotic distribution was described mainly from cerebrospinal fluid data, and only few data exist on brain extracellular fluid concentrations. The aim of this study was to describe brain distribution of cefotaxime (2 g/8 h) by microdialysis in patients with acute brain injury who were treated for a lung infection. Microdialysis probes were inserted into healthy brain tissue of five critical care patients. Plasma and unbound brain concentrations were determined at steady state by high-performance liquid chromatography. In vivo recoveries were determined individually using retrodialysis by drug. Noncompartmental and compartmental pharmacokinetic analyses were performed. Unbound cefotaxime brain concentrations were much lower than corresponding plasma concentrations, with a mean cefotaxime unbound brain-to-plasma area under the curve ratio equal to 26.1 ± 12.1%. This result was in accordance with the brain input-to-brain output clearances ratio (CL(in,brain)/CL(out,brain)). Unbound brain concentrations were then simulated at two dosing regimens (4 g every 6 h or 8 h), and the time over the MICs (T>MIC) was estimated for breakpoints of susceptible and resistant Streptococcus pneumoniae strains. T>MIC was higher than 90% of the dosing interval for both dosing regimens for susceptible strains and only for 4 g every 6 h for resistant ones. In conclusion, brain distribution of cefotaxime was well described by microdialysis in patients and was limited.
Asunto(s)
Antibacterianos/farmacocinética , Lesiones Encefálicas/metabolismo , Encéfalo/metabolismo , Cefotaxima/farmacocinética , Líquido Extracelular/metabolismo , Microdiálisis/métodos , Adulto , Anciano , Antibacterianos/sangre , Antibacterianos/uso terapéutico , Cefotaxima/sangre , Cefotaxima/uso terapéutico , Femenino , Humanos , Enfermedades Pulmonares/tratamiento farmacológico , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana EdadRESUMEN
BACKGROUND: Sample stability is critical for accurate analysis of drug compounds in biosamples. The use of additives to eradicate the enzymatic activity causing loss of these analytes has its limitations. RESULTS: A novel technique for sample stabilization by rapid, high-temperature heating was used. The stability of six commercial drugs in blood and blood spots was investigated under various conditions with or without heat stabilization at 95°C. Oseltamivir, cefotaxime and ribavirin were successfully stabilized by heating whereas significant losses were seen in unheated samples. Amodiaquine was stable with and without heating. Artemether and dihydroartemisinin were found to be very heat sensitive and began to decompose even at 60°C. CONCLUSION: Heat stabilization is a viable technique to maintain analytes in blood spot samples, without the use of chemical additives, by stopping the enzymatic activity that causes sample degradation.
Asunto(s)
Métodos Analíticos de la Preparación de la Muestra/métodos , Pruebas con Sangre Seca/métodos , Calor , Preparaciones Farmacéuticas/sangre , Preparaciones Farmacéuticas/metabolismo , Amodiaquina/sangre , Amodiaquina/metabolismo , Arteméter , Artemisininas/sangre , Artemisininas/metabolismo , Butirilcolinesterasa/metabolismo , Cefotaxima/sangre , Cefotaxima/metabolismo , Estabilidad de Medicamentos , Humanos , Oseltamivir/sangre , Oseltamivir/metabolismoRESUMEN
Influence of perfluorocarbon blood substitute Perftoran on pharmacokinetics of cefazolin (20 mg/kg), cefotaxime (25 mg/kg), ciprofloxacin (4 mg/kg) and pentoxifylline (10 mg/kg) upon their intravenous introduction separately or immediately after Perftoran infusion (5 ml/kg) was investigated on rabbits. It was found that the presence of Perftoran accelerated the transfer from blood to tissues for Cefazolin and Cefotaxime, which have negative values of the distribution logarithm in octanol/water (logP = -0.4 and -1.4, respectively). With respect to pentoxifylline and ciprofloxacin, which are less hydrophilic, the effect of pharmacokinetic interference was either weaker or absent. Probably, the infusion of hydrophobic Perftoran nanoemulsion enhances the hydrophobicity of blood plasma, which is a prerequisite for the more intensive transfer of hydrophilic ligands from blood to tissues.
Asunto(s)
Sustitutos Sanguíneos/farmacología , Cefazolina/farmacocinética , Cefotaxima/farmacocinética , Ciprofloxacina/farmacocinética , Fluorocarburos/farmacología , Pentoxifilina/farmacocinética , Animales , Cefazolina/sangre , Cefazolina/química , Cefotaxima/sangre , Cefotaxima/química , Ciprofloxacina/sangre , Ciprofloxacina/química , Interacciones Farmacológicas , Interacciones Hidrofóbicas e Hidrofílicas , Inyecciones Intravenosas , Masculino , Pentoxifilina/sangre , Pentoxifilina/química , ConejosRESUMEN
An HPLC method for the separation of seven cephalosporins [Cefepime (CEP), ceftazidime (CTA), ceftizaxime (CTI), ceftriaxone (CTR), cefotaxime (COT), cefixime (CIX) and cefoperazone (COP)] in human plasma and amniotic fluid has been developed. Optimization of the chromatographic method was performed in three steps: a series of initial experiments followed by two sets of experiments based on different experimental designs. The initial experiments were performed to decide the basic analytical requirements of the method. Then screening experiment fractional factorial design was used in order to decrease the number of parameters by eliminating parameters which having insignificant effect on responses. The parameters having significant effect were further optimized through a full factorial design. Having studied two responses (retention times and resolutions), a desirability function that assess the responses together, was used to find experimental conditions where the system generated desirable results. The desirable results were obtained with XTerra C18 (250 mm x 4.6mm, 5 microm i.d.) column, 40 mM phosphate buffer, pH 3.2, 18% MeOH, 0.85 mL min(-1) flow rate and 32 degrees C column temperature. Gradient elution with MeOH was applied. A simple and efficient solid-phase extraction was applied for the preparation of plasma and amniotic fluid samples. The validation parameters of the method were evaluated in accordance with ICH guideline. The method validated was applied to the analysis of CEP and COP in maternal venous, fetal venous and fetal arterial plasma, and to the analysis of CIX in maternal venous plasma and amniotic fluid.